known for decades that TS is expressed in tumor cells in quantities that are significantly higher than most noncancerous tissues. There has been much research into developing chemotherapeutic drugs which attempt to block or inhibit TS in tumor cells in an effort to shrink or slow their growth in vivo. Drugs such as fluorouracil and 5-flourouracil are examples of this class of TS inhibitors.

The problem with enzyme-inhibiting drugs is that over a short period of time, if the tumor cells are not killed, they become tremendously resistant to the inhibitors by various mechanisms. Usually the tumors boost expression of TS to overcome the inhibitor, but many other avenues are available to the tumor, such as pumping the drug out of the cell and mutating the enzyme to minimize the drug effect. At present, once the treated tumors start producing high levels of TS there is no effective therapy available.

Instead of inhibiting TS, this new strategy involves using TS to turn a uracil analog with low toxicity into highly toxic thymidine analog. The treatment would benefit patients with resistant tumors who were previously treated with TS inhibitors. The benefits of this type of prodrug are obvious. Patients could be treated with relatively high doses of the low toxicity prodrug thus ensuring high enough concentrations to penetrate the patients tissues and only the tumor cells will be actively converting the prodrug to its toxic metabolite thus dramatically lowering the severity of chemotherapeutic side effects. Moreover, there is less chance of the cells becoming resistant because they cannot down-regulate TS synthesis without slowing their own growth while making more and more toxic metabolites which in turn will kill the cancer cells.

Information about the patent application and pertinent information not yet publicly described can be obtained under a Confidential Disclosure Agreement. Respondees interested in licensing the invention(s) will be required to submit an Application for License to Public Health Service Inventions. Respondees interested in submitting a CRADA proposal should be aware that it may be necessary to secure a license to the above patent rights in order to commercialize products arising from a CRADA.
is hereby given of the following meeting of the National Cancer Institute Initial Review Group:

Agenda/Purpose: To review, discuss and evaluate individual grant applications.
Committee Name: Subcommittee H—Clinical Trials.
Date: March 24–25, 1998.
Time: March 24—8:00 a.m. to Recess; March 25—8:00 a.m. to Adjournment.
Place: DoubleTree Hotel, 1750 Rockville Pike, Rockville, Maryland 20852.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Research; 93.396, Cancer Detection and Diagnosis Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)
LaVerne Y. Stringfield,
Committee Management Officer, NIH.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Cancer Institute Initial Review Group:

Name of SEP: Long-term Cancer Survivors: Research Initiatives.
Date: March 17–20, 1998.
Time: March 17—7:00 p.m. to Recess; March 18 & 19—8:00 a.m. to Recess; March 20—8:00 a.m. to Adjournment.
Place: Holiday Inn—Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Wilma Woods, Ph.D, Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 622B, 6130 Executive Boulevard, Bethesda, MD 20892–7405, Telephone: 301/496–7903.

Purpose/Agenda: To review, discuss and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)
LaVerne Y. Stringfield,
Committee Management Officer, NIH.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Heart, Lung, and Blood Institute Special Emphasis Panel (SEP) meetings:

Name of SEP: Cooley’s Anemia Review Meeting.
Date: March 16–17, 1998.
Time: 8:00 p.m.
Place: Holiday Inn Bethesda, 8120 Wisconsin Avenue, Bethesda, Maryland 20814.
Contact Person: Eric H. Brown, Ph.D., Two Rockledge Center, Room 7204, 6701 Rockledge Drive, Bethesda, MD 20892–7924, (301) 435–0235.
Purpose/Agenda: To review and evaluate grant applications.

Name of SEP: Psychosocial Factors and Cardiovascular Disease.
Date: March 31, 1998.
Time: 8:00 a.m.
Place: Holiday Inn Bethesda, 8120 Wisconsin Avenue, Bethesda, Maryland 20814.
Contact Person: C. James Scheier, Ph.D., Two Rockledge Center, Room 7220, Bethesda, MD 20892–7924, (301) 435–0336.
Purpose/Agenda: To review and evaluate grant applications.

These meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Programs Nos. 93.835, Heart and Vascular Diseases Research; 93.836, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health).
LaVerne Y. Stringfield,
Committee Management Officer, NIH.